Literature DB >> 10825141

Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.

C A Omer1, Z Chen, R E Diehl, M W Conner, H Y Chen, M E Trumbauer, S Gopal-Truter, G Seeburger, H Bhimnathwala, M T Abrams, J P Davide, M S Ellis, J B Gibbs, I Greenberg, K S Koblan, A M Kral, D Liu, R B Lobell, P J Miller, S D Mosser, T J O'Neill, E Rands, M D Schaber, E T Senderak, A Oliff, N E Kohl.   

Abstract

For Ras oncoproteins to transform mammalian cells, they must be posttranslationally modified with a farnesyl group in a reaction catalyzed by the enzyme farnesyl:protein transferase (FPTase). Inhibitors of FPTase have therefore been developed as potential anticancer agents. These compounds reverse many of the malignant phenotypes of Ras-transformed cells in culture and inhibit the growth of tumor xenografts in nude mice. Furthermore, the FPTase inhibitor (FTI) L-744,832 causes tumor regression in mouse mammary tumor virus (MMTV)-v-Ha-ras transgenic mice and tumor stasis in MMTV-N-ras mice. Although these data support the further development of FTIs, it should be noted that Ki-ras is the ras gene most frequently mutated in human cancers. Moreover, Ki-RasB binds more tightly to FPTase than either Ha- or N-Ras, and thus higher concentrations of FTIs that are competitive with the protein substrate may be required to inhibit Ki-Ras processing. Given the unique biochemical and biological features of Ki-RasB, it is important to evaluate the efficacy of FTIs or any other modulator of oncogenic Ras function in model systems expressing this Ras oncoprotein. We have developed strains of transgenic mice carrying the human Ki-rasB cDNA with an activating mutation (G12V) under the control of the MMTV enhancer/promoter. The predominant pathological feature that develops in these mice is the stochastic appearance of mammary adenocarcinomas. High levels of the Ki-rasB transgene RNA are detected in these tumors. Treatment of MMTV-Ki-rasB mice with L-744,832 caused inhibition of tumor growth in the absence of systemic toxicity. Although FPTase activity was inhibited in tumors from the treated mice, unprocessed Ki-RasB was not detected. These results demonstrate the utility of the MMTV-Ki-rasB transgenic mice for testing potential anticancer agents. Additionally, the data suggest that although the FTI L-744,832 can inhibit tumor growth in this model, Ki-Ras may not be the sole mediator of the biological effects of the FTI.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10825141

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors.

Authors:  Norbert Berndt; Saïd M Sebti
Journal:  Nat Protoc       Date:  2011-10-27       Impact factor: 13.491

2.  The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2.

Authors:  X Zeng; F Y Shaikh; M K Harrison; A M Adon; A J Trimboli; K A Carroll; N Sharma; C Timmers; L A Chodosh; G Leone; H I Saavedra
Journal:  Oncogene       Date:  2010-06-28       Impact factor: 9.867

Review 3.  Farnesyltransferase inhibitors: potential role in the treatment of cancer.

Authors:  A D Cox
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Conditional expression of Ki-RasG12V in the mammary epithelium of transgenic mice induces estrogen receptor alpha (ERα)-positive adenocarcinoma.

Authors:  S Andò; R Malivindi; S Catalano; P Rizza; I Barone; S Panza; D Rovito; C Emprou; J-M Bornert; G Laverny; D Metzger
Journal:  Oncogene       Date:  2017-07-24       Impact factor: 9.867

5.  Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.

Authors:  Meng Liu; Anna-Karin M Sjogren; Christin Karlsson; Mohamed X Ibrahim; Karin M E Andersson; Frida J Olofsson; Annika M Wahlstrom; Martin Dalin; Huiming Yu; Zhenggang Chen; Shao H Yang; Stephen G Young; Martin O Bergo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

Review 6.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

7.  Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras.

Authors:  Katrina Podsypanina; Katerina Politi; Levi J Beverly; Harold E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-20       Impact factor: 11.205

8.  Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells.

Authors:  Yuan Huang; Fatima Rangwala; Patricia C Fulkerson; Bo Ling; Erin Reed; Adrienne D Cox; John Kamholz; Nancy Ratner
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

9.  Caution! Analyze transcripts from conditional knockout alleles.

Authors:  Shao H Yang; Martin O Bergo; Emily Farber; Xin Qiao; Loren G Fong; Stephen G Young
Journal:  Transgenic Res       Date:  2008-12-18       Impact factor: 2.788

10.  Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf.

Authors:  Martin O Bergo; Bryant J Gavino; Christine Hong; Anne P Beigneux; Martin McMahon; Patrick J Casey; Stephen G Young
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.